194423-79-5

Basic information

• Product Name: ETHYL 3-CHLORO-7-(TRIFLUOROMETHYL)QUINOXALINE-2-CARBOXYLATE
• Synonyms: ETHYL 3-CHLORO-7-(TRIFLUOROMETHYL)QUINOXALINE-2-CARBOXYLATE
• CAS NO: 194423-79-5
• Molecular Formula: C₁₂H₈ClF₃N₂O₂
• Molecular Weight: 304.65
• Mol File: 194423-79-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 3-CHLORO-7-(TRIFLUOROMETHYL)QUINOXALINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-CHLORO-7-(TRIFLUOROMETHYL)QUINOXALINE-2-CARBOXYLATE(194423-79-5)
• EPA Substance Registry System: ETHYL 3-CHLORO-7-(TRIFLUOROMETHYL)QUINOXALINE-2-CARBOXYLATE(194423-79-5)

Safety Data

• Hazardous Substances Data: 194423-79-5(Hazardous Substances Data)

Upstream product

• 143948-79-2 ethyl 3-oxo-7-(trifluoromethyl)-3,4-dihydroquinoxaline-2-carboxylate 
• 368-71-8 4-(trifluoromethyl)-1,2-phenylenediamine 
• 609-09-6 Diethyl ketomalonate 

Downstream Products

• 194423-93-3 3-(4-Ethoxycarbonyl-phenylamino)-7-trifluoromethyl-quinoxaline-2-carboxylic acid ethyl ester 
• 194424-10-7 (S)-2-[4-(3-Ethoxycarbonyl-6-trifluoromethyl-quinoxalin-2-ylamino)-benzoylamino]-pentanedioic acid diethyl ester 

Relevant articles and documents

New quinoxaline derivatives as dual pim-1/2 kinase inhibitors: Design, synthesis and biological evaluation

Proviral integration site for Moloney murine leukemia virus (Pim)-1/2 kinase overexpression has been identified in a variety of hematologic (e.g., multiple myeloma or acute myeloid leukemia (AML)) and solid (e.g., colorectal carcinoma) tumors, playing a key role in cancer progression, metastasis, and drug resistance, and is linked to poor prognosis. These kinases are thus considered interesting targets in oncology. We report herein the design, synthesis, structure–activity relationships (SAR) and in vitro evaluations of new quinoxaline derivatives, acting as dual Pim1/2 inhibitors. Two lead compounds (5c and 5e) were then identified, as potent submicromolar Pim-1 and Pim-2 inhibitors. These molecules were also able to inhibit the growth of the two human cell lines, MV4-11 (AML) and HCT-116 (colorectal carcinoma), expressing high endogenous levels of Pim-1/2 kinases.

TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS

The present invention provides a tri-substituted pyrimidine compound having an excellent PDE10 inhibitory activity. The present invention relates to a tri-substituted pyrimidine compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compound for PDE10 inhibitor, and a pharmaceutical composition comprising said compounds as an active ingredient: wherein: either one of X1 and X2 is N, and the other of X1 and X2 is CH; A is *-CH═CH—, *-C(Alk)=CH—, *-CH2—CH2— or *-O—CH2— (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted quinoxalinyl or an optionally substituted quinolyl; Y0 is mono- or di-substituted amino group, or a pharmaceutically acceptable salt thereof.

Quinoxaline chemistry. Part 7. 2-[aminobenzoates]- and 2- [aminobenzoylglutamate]-quinoxalines as classical antifolate agents. Synthesis and evaluation of in vitro anticancer, anti-HIV and antifungal activity

Thirty-three quinoxalines bearing an aminobenxoyl or aminobenzoylglutammate group on position 2 and various substituents on position 3,6,7 of the heterocycle were prepared in order to evaluate in vitro anticancer activity. Preliminary screening performed at NCI showed that most derivatives exhibited a moderate to strong growth inhibition activity on various tumor panel cell lines between 10-5 and 10-4 molar concentrations. Interesting selectivities were also recorded between 10-8 and 10-6. Among the series examined one compound (29) which was the most active also exhibited both in vitro anti-HIV protection and antifungal activity while in other two (31.37) the antifungal activity was prevailing.